About
Here you will find summaries of all the latest publications on lupus, focusing on those covering treatments, recommendations and other topics that may influence clinical practice.
Latest Updates
All ▼
Remission of Lupus Nephritis: The Trajectory of Histological Response in Successfully Treated Patients
Does Remission in Systemic Lupus Erythematosus According to the 2021 DORIS Definition Match the Treating Rheumatologist’s Judgment?
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Changes in Discrete Subsets of Blood Transcriptomic and Cellular Biomarkers
Sustained Glucocorticoid Tapering in the Phase 3 Trials of Anifrolumab: A post hoc Analysis of the TULIP-1 and TULIP-2 Trials
Evaluation of the LFA-REAL Clinician-reported Outcome (ClinRO) and Patient-reported Outcome (PRO): Prespecified Analysis of the Phase III Ustekinumab Trial in Patients with SLE
Baricitinib for Systemic Lupus Erythematosus: a Double-blind, Randomised, Placebo-controlled, Phase 3 trial (SLE-BRAVE-II)
Baricitinib for Systemic Lupus Erythematosus: a Double-blind, Randomised, Placebo-controlled, Phase 3 Trial (SLE-BRAVE-I)
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling
Lupus Low Disease Activity State Attainment in the Phase 3 TULIP Trials of Anifrolumab in Active Systemic Lupus Erythematosus
Relationship Between the EULAR/ACR Classification Criteria and Organ Damage in Systemic Lupus Erythematosus
Aurinia Announces European Approval of LUPKYNIS (voclosporin)
Jourde-Chiche et al, 2022
van Vollenhoven et al, 2022
Dörner et al, 2022
Literature Highlights, July 2022
Furie et al, 2021
Literature Highlights, October 2021
Iolascon et al, 2021
